← DPP-4 inhibitors × cardiovascular events

Observational studyDiabetes, obesity & metabolism2017

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.

Jason Gordon et al.PubMed ↗Full text ↗Publisher ↗

  • Metformin + DPP-4 inhibitorlooks good hereLower total event rates for MACE, lower MI rate.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Metformin + DPP-4 inhibitor went with lower total event rates for MACE

−39%−61% to −2%

metformin + DPP-4 inhibitor vs metformin + SU

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.39–0.98

Correlation, not cause

Metformin + DPP-4 inhibitor went with lower MI rate

−48%−73% to −1%

metformin + DPP-4 inhibitor vs metformin + SU

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.52, 95% CI 0.27–0.99

Who was studied, and how

484people with type 2 diabetes, in this paper

Already taking metformin + DPP-4 inhibitor, or nottheir own situation, not assigned

on metformin + DPP-4 inhibitor
metformin + SU

Metformin + DPP-4 inhibitor went with lower total event rates for MACE−39%

Metformin + DPP-4 inhibitor went with lower MI rate−48%

correlation, not a test

the abstract, start to end

… lower than with metformin + SU (0.61, 95% confidence interval [CI] 0.39-0.98), driven by a lower MI rate in the metformin + DPP-4 inhibitor group (0.52, 95% CI 0.27-0.99).

← favours treatmentfavours comparator →
could be chance
Total event rates for MACEmetformin + DPP-4 inhibitor vs metformin + SU
HR 0.610.39–0.98
MI ratemetformin + DPP-4 inhibitor vs metformin + SU
HR 0.520.27–0.99
MetforminDPP-4 inhibitorsCardiovascular events
1 / 4

9 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28026911